Source-grounded facts extracted from Cardiff Oncology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cardiff Oncology, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-11 meeting.
“Proposal 4. The advisory vote on the compensation of the Company's named executive officers was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 17,120,176 1,772,185 437,049 22,285,438”
Cardiff Oncology, Inc. shareholders approved Amendment to 2021 Equity Incentive Plan to increase number of shares issuable to 15,150,000 shares at the 2026-06-11 meeting.
“Proposal 3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 10,740,460 8,063,520 525,431 22,285,437”
Cardiff Oncology, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year 2026 at the 2026-06-11 meeting.
“Proposal 2. The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 40,239,508 1,070,807 304,529 4”
Cardiff Oncology, Inc. shareholders approved Election of six nominees for director at the 2026-06-11 meeting.
“Proposal 1 . All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the six (6) directors was as follows: Directors For Against Abstain Broker Non Vote Dr. James O. Armitage 18,806,657 0 522,756 22,285,435 Dr. Rodney Markin 18,647,050 0 682,361 22,285,437 Mani Mohindru, Ph.D. 18,942,979 0 386,435 22,285,434 Gary W. Pace, Ph.D. 18,877,743 0 451,668 22,285,437 Renee P. Tannenbaum, Pharm.D. 18,790,068 0 539,345 22,285,435 Lâle White 18,710,040 0 619,373 22,285,435”
Cardiff Oncology, Inc. terminated License Agreement with Nerviano Medical Sciences S.r.l. (effective 2026-05-27).
“On May 27, 2026, the Company was informed in writing by NMS that NMS was terminating the Agreement pursuant to Section 11.3 of the Agreement.”
Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 14, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the first quarter ended March 31, 2026.”
Dr. Roger Sidhu was appointed as Chief Medical Officer at Cardiff Oncology, Inc..
“On June 17, 2025, the Company announced that it has appointed Dr. Roger Sidhu as its new Chief Medical Officer and entered into an employment agreement with Dr. Sidhu on June 16, 2025 (the “Sidhu Employment Agreement”).”
Dr. Fairooz Kabbinavar departed as Chief Medical Officer at Cardiff Oncology, Inc..
“On June 13, 2025, Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc. (the “Company”) agreed that he would be stepping down from his position as Chief Medical Officer.”
Cardiff Oncology, Inc.: The Board of Directors approved Amended and Restated By-laws (effective 2025-01-03).
“On January 3, 2025, the Board of Directors of Cardiff Oncology, Inc. (the “Company”) approved the Amended and Restated By-laws of the Company.”
Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 2, 2024, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2024 .”
Cardiff Oncology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 29, 2024, Cardiff Oncology, Inc. (the “Company”) issued a press release announcing company highlights and financial results for the fourth quarter and full year ended December 31, 2023.”
Cardiff Oncology, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2023.”
Cardiff Oncology, Inc. reported financial results for second quarter ended June 30, 2023.
“On August 9, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the second quarter ended June 30, 2023.”
Cardiff Oncology, Inc.: Filed Certificate of Elimination to remove designations of Series B, C, D, and E Convertible Preferred Stock, returning those shares to authorized but unissued preferred stock (effective 2023-08-08).
“On August 8, 2023, Cardiff Oncology, Inc. (the “Company”) filed, with the Secretary of State of the State of Delaware, a Certificate of Elimination (the “Certificate of Elimination”) of Series B, Series C, Series D and Series E Convertible Preferred Stock removing the designation and other references to its Series B, Series C, Series D and Series E Convertible Stock from the Company’s Amended and Restated Certificate of Incorporation, as amended.”
Cardiff Oncology, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-15 meeting.
“Proposal 4. The advisory vote on the compensation of the Company’s named executive officers was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 11,916,210 2,419,195 292,665 12,671,079”
Cardiff Oncology, Inc. shareholders approved Advisory vote on frequency of shareholder vote on named executive officer compensation at the 2023-06-15 meeting.
“Proposal 3. A one year frequency of the advisory shareholder vote on the Company’s named executive officer compensation, as recommended by the Board of Directors, was approved by the stockholders by the votes set forth in the table below: 1 Year 2 Years 3 Years Abstain Broker Non Vote 13,681,338 142,222 696,088 108,422 12,671,079”
Cardiff Oncology, Inc. shareholders approved Ratification of appointment of BDO USA, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
“Proposal 2. The appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 26,560,889 560,805 177,454 1”
Cardiff Oncology, Inc. shareholders approved Election of seven directors to serve until the 2024 Annual Meeting at the 2023-06-15 meeting.
“Proposal 1 . All of the seven (7) nominees for director were elected to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the seven (7) directors was as follows: Directors For Against Abstain Broker Non Vote Mark Erlander, Ph.D. 13,865,171 0 762,900 12,671,078 Dr. Rodney Markin 13,876,802 0 751,269 12,671,078 Dr. James O. Armitage 13,890,969 0 737,101 12,671,079 Lale White 13,785,160 0 842,910 12,671,079 Gary W. Pace, Ph.D. 14,140,640 0 487,431 12,671,078 Mani Mohindru, Ph.D. 12,545,020 0 2,083,050 12,671,079 Renee P. Tannenbaum, Pharm.D. 13,880,230 0 747,841 12,671,078”
Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2023.
“On May 4, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2023.”
Cardiff Oncology, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
“On March 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.”
Fairooz Kabbinavar was appointed as Chief Medical Officer at Cardiff Oncology, Inc..
“On January 30, 2023, Cardiff Oncology, Inc. (the “Company”) appointed Dr. Fairooz Kabbinavar as Chief Medical Officer of the Company”
Cardiff Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2022.”
Sandra L. Silberman, M.D., Ph.D. was appointed as senior medical advisor at Cardiff Oncology, Inc..
“Sandra L. Silberman, M.D., Ph.D., who previously acted as a chief medical advisor to Cardiff Oncology from June 2017 to July 2021, has agreed to serve as the Company’s senior medical advisor and oversee its clinical trials and clinical operations team on an interim basis.”
Katherine Ruffner, M.D. resigned as Chief Medical Officer at Cardiff Oncology, Inc..
“On April 12, 2022, Cardiff Oncology, Inc. (the “Company”) announced that Katherine Ruffner, M.D., the Company’s Chief Medical Officer, will be leaving the Company on April 22, 2022, to pursue a new opportunity.”
James Levine was appointed as Chief Financial Officer at Cardiff Oncology, Inc..
“In addition, on July 12, 2021, the Company entered into an employment agreement with James Levine (the “Levine Employment Agreement”) pursuant to which Mr. Levine will be the Chief Financial Officer of the Company.”
Katherine Ruffner was appointed as Chief Medical Officer at Cardiff Oncology, Inc..
“On July 6, 2021, Cardiff Oncology, Inc. (the “Company”) appointed Dr. Katherine Ruffner as Chief Medical Officer of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.